Touchlight, a global leader in cell-free DNA technology, announced the expansion of its groundbreaking mbDNA platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA. These innovative constructs join mbDNA, which launched earlier this year, creating a comprehensive portfolio designed to overcome the limitations of traditional gene editing tools.

The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies—setting a new benchmark for precision, safety, and scalability in genetic engineering.

mbDNA (megabulb DNA) is a pioneering single-stranded DNA technology produced through Touchlight’s proprietary cell-free enzymatic platform. It offers exceptional purity, minimal immunogenicity, and robust reliability for large-scale production. With high homology-directed repair (HDR) efficiency and low toxicity, mbDNA consistently achieves knock-in rates of 60–75 per cent in primary T cells. Its expanded payload capacity of up to 20kb enables the delivery of large genetic cargos, opening new possibilities for complex gene editing applications.

The new DNA architectures further extend this versatility. sscDNA is a fully single-stranded circular DNA molecule, while hsscDNA incorporates user-defined double-stranded regions for added flexibility. dscDNA, a fully double-stranded circular molecule, supports a wide range of gene delivery strategies. Each construct is completely customizable, making them ideal for applications involving transposases, recombinases, homology-independent targeted integration (HITI), and episomal expression.

“The mbDNA platform is a market-leading technology offering the best-in-class HDR template available today,” said Karen Fallen, CEO of Touchlight. “By introducing sscDNA, hsscDNA, and dscDNA, we are empowering scientists and developers to explore new frontiers in gene editing and therapeutic innovation.”

The flexible and customizable nature of Touchlight’s novel circular DNA molecules makes them ideal for next-generation gene therapy platforms that require precise, stable, and scalable DNA payloads for episomal expression or genomic integration.